• Home
  • Search Results
  • Protective Effect of α-Linolenic Acid on Non-Alcoholic Hepatic Steatosis and Interleukin-6 and -10 in Wistar Rats.

Protective Effect of α-Linolenic Acid on Non-Alcoholic Hepatic Steatosis and Interleukin-6 and -10 in Wistar Rats.

Nutrients (2019-12-22)
Camila Jordão Candido, Priscila Silva Figueiredo, Rafael Del Ciampo Silva, Luciane Candeloro Portugal, Jeandre Augusto Dos Santos Jaques, Jeeser Alves de Almeida, Bruna de Barros Penteado, Dhébora Albuquerque Dias, Gabriela Marcelino, Arnildo Pott, Rita de Cássia Avellaneda Guimarães, Priscila Aiko Hiane
ABSTRACT

Consumption of omega-3 (n-3) polyunsaturated fatty acids (PUFA) is related to improvement in the inflammatory response associated with decreases in metabolic disorders of obesity, such as low-grade inflammation and hepatic steatosis. Linseed (Linum usitatissimum) oil is a primary source of n-3 fatty acids (FAs) of plant origin, particularly α-linolenic acid, and provides an alternative for the ingestion of n-3 PUFA by persons allergic to, or wishing to avoid, animal sources. In our study, we evaluated the effect of the consumption of different lipidic sources on metabolic and inflammatory parameters in Wistar rats. We split 56 male rats into four groups that were fed for 60 days with the following diets: sesame oil, (SO, Sesamum indicum), linseed oil (LO), SO + LO (SLO), and a control group (CG) fed with animal fat. Our results reveal that the use of LO or SLO produced improvements in the hepatic tissue, such as lower values of aspartate aminotransferase, liver weight, and hepatic steatosis. LO and SLO reduced the weight of visceral fats, weight gain, and mediated the inflammation through a decrease in interleukin (IL)-6 and increase in IL-10. Though we did not detect any significant differences in the intestine histology and the purinergic system enzymes, the consumption of α-linolenic acid appears to contribute to the inflammatory and hepatic modulation of animals compared with a diet rich in saturated FAs and or unbalanced in n-6/n-3 PUFAs, inferring possible use in treatment of metabolic disorders associated with obesity and cardiovascular diseases.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Bovine Serum Albumin, lyophilized powder, ≥96% (agarose gel electrophoresis)
Sigma-Aldrich
Adenosine 5′-diphosphate sodium salt, bacterial, ≥95% (HPLC)
Sigma-Aldrich
HEPES sodium salt, ≥99.5% (titration)
Sigma-Aldrich
Adenosine 5′-triphosphate disodium salt hydrate, microbial, BioReagent, suitable for cell culture, ≥99% (HPLC)
Sigma-Aldrich
Trichloroacetic acid, ≥99.0% (titration)
Sigma-Aldrich
Adenosine 5′-monophosphate sodium salt, from yeast, ≥99%